JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

doi:10.1172/JCI94516

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

The Journal of clinical investigation - 1 Feb 2018

McKenney Anna Sophia, Lau Allison N, Somasundara Amritha Varshini Hanasoge, Spitzer Barbara, Intlekofer Andrew M, Ahn Jihae, Shank Kaitlyn, Rapaport Franck T, Patel Minal A, Papalexi Efthymia, Shih Alan H, Chiu April, Freinkman Elizaveta, Akbay Esra A, Steadman Mya, Nagaraja Raj, Yen Katharine, Teruya-Feldstein Julie, Wong Kwok-Kin, Rampal Raajit, Vander Heiden Matthew G, Thompson Craig B, Levine Ross L

Abstract excerpt

Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor outcomes. Here, we showed that combined expression of Jak2V617F and mutant IDH1R132H or Idh2R140Q induces MPN progression, alters stem/progenitor cell function, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Epigenesis, Genetic

Share to Isocitrate Dehydrogenase

Share to Janus Kinase 2

Share to Mice, Mutant Strains

Share to Myeloproliferative Disorders

Share to Stem Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 29355841
DOI: 10.1172/JCI94516
PMCID: PMC5785272

Genes

JAK2
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.PMID 29355841Read ↗

IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation.Semantic proximity Read ↗

Mutant IDH1 cooperates with NPM1c or FLT3 ITD to drive distinct myeloid diseases and molecular outcomesSemantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosisSemantic proximity Read ↗

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.Semantic proximity Read ↗

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.Semantic proximity Read ↗

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.Semantic proximity Read ↗

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Semantic proximity Read ↗

Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.